The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 201–300 of 961
Schreiber, C. P., Kovacik, A. J., Bishop, J., & Helman, J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01253-x · Cited by 15
Benina, N., Buitrago, L., Simone, F. I. D., Radwan, R. R., Miller, M. C., Martin, K., Dickson, D. L., Ho, S. G., Moghekar, A., Albert, M., et al. (2026) · Brain · doi:10.1093/brain/awag001 · Cited by 15
Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications
Vossel, K. A., Johnson, E. L., Cretin, B., & Matsumoto, R. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00425-9 · Cited by 15
Zadrożny, M., Drapich, P., Gąsiorowska, A., Niewiadomski, W., Harrington, C. R., Wischik, C. M., Riedel, G., & Niewiadomska, G. (2024) · Cells · doi:10.3390/cells13070642 · Cited by 13
Ozawa, T., Franguridi, G., & Mattke, S. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.81 · Cited by 13
Soleimani‐Meigooni, D. N., Smith, R. A., Provost, K., Lesman‐Segev, O. H., Allen, I. E., Chen, M. K., Cho, H., Edwards, L., Janelidze, S., Joie, R. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27008 · Cited by 13
Self-citationRoberts, W. S., Price, S., Wu, M., & Parmar, M. S. (2024) · Cureus · doi:10.7759/cureus.67037 · Cited by 17
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 14
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 17
Atypical Presentations of Alzheimer Disease
Jones, D. T., Pelak, V. S., & Rogalski, E. J. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001504 · Cited by 13
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab
Ji, S.-M., & Rosenbloom, M. H. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01640-3 · Cited by 13
Hayes, C. A., Young, C. B., Ruiz, C. A., Reeves, A. N., Odden, M. C., Nirschl, J., Crane, P. K., Poston, K. L., Mormino, E. C., & Younes, K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70059 · Cited by 16
A Review of Machine Learning Approaches for Non-Invasive Cognitive Impairment Detection
Alsuhaibani, M., Fard, A. P., Sun, J., Poor, F. F., Pressman, P., & Mahoor, M. H. (2025) · IEEE Access · doi:10.1109/access.2025.3555176 · Cited by 20
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
Yan, L., Zhang, L., Xu, Z., & Luo, Z. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559447 · Cited by 13
Parks, A. L., Thacker, A., Dohan, D. P., Gomez, L. A. R., Ritchie, C. S., Paladino, J., & Shah, S. J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329519 · Cited by 15
Staging Alzheimer’s disease through amyloid and tau PET
Johnson, D. R., Wiste, H. J., Lowe, V. J., Schwarz, C. G., Knopman, D. S., Vemuri, P., Kantarci, K., Boeve, B. F., Graff‐Radford, J., Cogswell, P. M., et al. (2025) · Brain · doi:10.1093/brain/awaf346 · Cited by 13
Self-citationRosenberg, A., Solomon, A., Bonnard, A., Daniilidou, M., Hagman, G., Hall, A., Matton, A., Öhlund‐Wistbacka, U., Westman, E., & Kivipelto, M. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100476 · Cited by 12
Kodali, M. C., Antone, J., Alsop, E. B., Jayakumar, R., Parikh, K., Chiot, A., Sanchez-Molina, P., Ajami, B., Arnold, S. E., Jensen, K., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03047-1 · Cited by 12
Day, G. S. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001507 · Cited by 12
Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenigro, P. H., Siemers, E., Sink, K. M., Shaw, L. M. J., Hansen, C. T., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70013 · Cited by 15
Asken, B. M., Curiel, R. E., Crocco, E., Armstrong, M. J., Levy, S.-A. T., Arias, F., Rosselli, M., Vélez-Uribe, I., Barker, W., Matusz, E. F., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100011 · Cited by 14
Ashmawy, R. E., Okesanya, O. J., Ukoaka, B. M., Daniel, F. M., Ezedigwe, S. G., Agboola, A. O., Ahmed, M. M., Ogaya, J. B., Amisu, B. O., Adigun, O. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331640 · Cited by 13
Ghaffar, U., Batool, Z., Tasleem, M., Sadeghian, N., Taslımı, P., Mali, S. N., Dahlous, K. A., Jawarkar, R. D., Gurav, S. S., Zhao, X., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70034 · Cited by 12
Patel, S., Thornton, A., & Parmar, M. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05234-4 · Cited by 13
Bonomi, S., Gupta, M. R., & Schindler, S. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13473 · Cited by 12
Profiling lecanemab as a treatment option for Alzheimer’s disease
Schiller, E. R., Silverglate, B., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333970 · Cited by 14
Clinical Implementation of Lecanemab: Challenges, Questions and Solutions
Iwatsubo, T. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.41 · Cited by 12
Daniilidou, M., Öhlund‐Wistbacka, U., Hagman, G., Rosenberg, A., Ashton, N. J., Zetterberg, H., Blennow, K., Matton, A., & Kivipelto, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70931 · Cited by 11
Shim, G. H., Lau, E. C. Y., Huynh, A. L. H., Lu, C. Y., & Tan, E. C. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102981 · Cited by 11
Filippi, M., Cecchetti, G., Spinelli, E. G., Ghirelli, A., Rugarli, G., Pisano, S., Canu, E., & Agosta, F. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101609 · Cited by 14
van Etten, E. S., Mahinrad, S., Grill, J. D., Salloway, S., Atri, A., Cogswell, P. M., Benzinger, T. L. S., Iwatsubo, T., Iadecola, C., Lemere, C. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71361 · Cited by 16
Self-citationRecent advances in understanding Alzheimer’s Disease: diagnosis and management strategies
Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 12
Beveridge, J., Kaniecki, E., Naidu, A., Silverglate, B., & Grossberg, G. T. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2304059 · Cited by 13
Mattke, S., Shi, Z., Hanson, M., Mitchell, S., Lynch, C., Kalonji, K. M., & Lanman, L. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.24 · Cited by 11
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Projected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic
Connolly, E., O’Connor, A., Dolphin, H., Dyer, A. H., Fallon, A., O’Dowd, S., & Kennelly, S. (2024) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6157 · Cited by 11
Karneboge, J. N., Haberstroh, J., Geschke, K., Perry, J., Radenbach, K., Jessen, F., & Rostamzadeh, A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14204 · Cited by 11
Cox, C. G., Kirch, M., Singer, D., Solway, E. S., Malani, P., Kullgren, J. T., & Roberts, J. S. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70067 · Cited by 11
Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics
Kang, S. H., Jeong, J. H., Pyun, J., Kim, G. H., Park, Y. H., Shim, Y., Koh, S., Kim, C., Youn, Y. C., Yang, D. W., et al. (2025) · Journal of Clinical Neurology · doi:10.3988/jcn.2024.0550 · Cited by 11
Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease
Nakashima, S., Sato, K., Niimi, Y., Ihara, R., Suzuki, K., Iwata, A., Toda, T., Iwatsubo, T., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70102 · Cited by 11
Chen, Y., Zeng, X., Olvera‐Rojas, M., Sewell, K. R., Sehrawat, A., Gu, J. M., Triviño‐Ibáñez, E. M., Solis‐Urra, P., Gómez-Río, M., Oberlin, L. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68372-w · Cited by 13
Shang, J., Zhong, S., Shang, L., Zeng, Q., Zhao, S., Luo, X., Li, K., Zhang, X., Huang, P., Yan, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01886-5 · Cited by 13
Menuawy, A. E., Brüning, T., Eiriz, I., Hähnel, U., Marthe, F., Möhle, L., Górska, A. M., Santos‐García, I., Wangensteen, H., Wu, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021301 · Cited by 11
Pan, Y., Li, Z., Zhao, X., Du, Y., Zhang, L., Lu, Y.-S., Yang, L., Cao, Y., Qiu, J., & Qian, Y. (2024) · Foods · doi:10.3390/foods13040612 · Cited by 11
Geerts, H., Bergeler, S., Walker, M., Rose, R. H., & van der Graaf, P. H. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12474 · Cited by 12
Colmenares, A. M., Thomas, M. L., Anderson, C., Arciniegas, D. B., Calhoun, V. D., Choi, I., Kramer, A. F., Li, K., Lee, J., Lee, P., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.05.013 · Cited by 12
Lee, D. D., Antonsdottir, I. M., Clark, E. D., & Porsteinsson, A. P. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2360069 · Cited by 11
Manjavong, M., Diaz, A., Ashford, M. T., Aaronson, A., Miller, M. J., Kang, J., Mackin, S., Tank, R., Landavazo, B., Truran, D., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.109 · Cited by 9
Self-citationDiagnosis and Management of Progressive Corticobasal Syndrome
Nouh, C. D., & Younes, K. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00797-4 · Cited by 11
Huang, B., Sawicki, S., Habiger, C., Mattis, P. J., Gordon, M. L., Franceschi, A. M., & Giliberto, L. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1428036 · Cited by 10
Silbert, L. C. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001508 · Cited by 11
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer’s disease
Zhou, R. Z., Gaunitz, S., Kirsebom, B., Lundin, B., Hellström, M., Jejcic, A., Sköldunger, A., Wimo, A. B., Winblad, B. G., Fladby, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105598 · Cited by 10
Hu, H., Zhao, Y., Mao, J., He, J., Zhang, Y., Ye, H., & Yang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561020 · Cited by 11
Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial
Kutzsche, J., Cosma, N. C., Kauselmann, G., Fenski, F., Bieniek, C., Bujnicki, T., Pils, M., Bannach, O., Willbold, D., & Peters, O. (2025) · Nature Communications · doi:10.1038/s41467-025-59295-z · Cited by 10
Doxycycline: An essential tool for Alzheimer’s disease
Forloni, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118159 · Cited by 11
Windon, C., Gatsonis, C. A., Carrillo, M. C., Romanoff, J., Hanna, L., Glavin, E. E., Gareen, I. F., Gutman, R., Hillner, B. E., March, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70504 · Cited by 11
Self-citationReview of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer’s disease
Francis, E., Paylor, S., Van, C., Mathews, B., Sobhanian, M. J., Mansour, D. Z., Hennawi, G., & Brandt, N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2556122 · Cited by 10
Aguilar, B. J., Miller, D. R., Jasuja, G. K., Li, X., Shishova, E. Y., O’Connor, M. K., Nguyen, A. H., Morin, P., Berlowitz, D. R., Zhang, R. J., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00540-2 · Cited by 10
Dementia research in 2023: the year of anti-amyloid immunotherapy
Delrieu, J., Andrieu, S., & Vellas, B. J. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00449-0 · Cited by 10
Risacher, S. L. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001509 · Cited by 11
Canu, E., Rugarli, G., Coraglia, F., Basaia, S., Cecchetti, G., Calloni, S. F., Vezzulli, P. Q., Spinelli, E. G., Santangelo, R., Caso, F., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12221-7 · Cited by 10
Leroi, I., Dolphin, H., Dinh, R., Foley, T., Kennelly, S., Kinchin, I., Ó’Caoimh, R., O’Dowd, S., O’Philbin, L., O’Reilly, S., et al. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11019-7 · Cited by 11
Bhalala, O. G., Thompson, J., Watson, R., & Yassi, N. (2024) · The Medical Journal of Australia · doi:10.5694/mja2.52359 · Cited by 9
Lee, J. H., Jia, J., Ji, Y., Kandiah, N., Kim, S., Mok, V., Pai, M., Senanarong, V., Suh, C. H., & Chen, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240684 · Cited by 9
Amyloid-Directed Antibodies: Past, Present, and Future
Noorda, K., Noorda, K. J., Sabbagh, M. N., Bertelson, J. A., Singer, J., & Decourt, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240189 · Cited by 9
Transethnic analysis identifies SORL1 variants and haplotypes protective against Alzheimer's disease
Zhou, X., Cao, H., Jiang, Y., Chen, Y., Zhong, H., Fu, W. Y., Lo, R. M. N., Wong, B. W. Y., Cheng, E. Y. L., Mok, K. Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14214 · Cited by 9
Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions
Knopman, D. S. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14043 · Cited by 9
Precision Medicine in Parkinson’s Disease
Eshed, G. M., & Alcalay, R. N. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2024.12.011 · Cited by 8
Jeon, S. Y., Wang, S., Roh, H. W., Kim, K. Y., Chang, Y. Y., Kim, E., Bae, J. N., & Ryu, S. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e215 · Cited by 9
Cogswell, P. M., Wiste, H. J., Therneau, T. M., Griswold, M. E., Mattsson, N., Palmqvist, S., Binette, A. P., Stomrud, E., Bateman, R. J., Barthélemy, N. R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70625 · Cited by 9
Self-citationDeep cervical lymphaticovenous anastomosis for Alzheimer's disease: A narrative review
Chen, Q., Wen, Q., Zhong, T. P., Liu, J., & Gao, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71038 · Cited by 9
Appropriate Use Recommendations for Lecanemab
Rafii, M. S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.34 · Cited by 9
Dyer, A. H., Dolphin, H., Shenkin, S. D., Welsh, T. J., Soysal, P., Roitto, H., Religa, D., Kennelly, S., on behalf of the EuGMS Special Interest Group in Dementia, Söylemez, B. A., et al. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00846-2 · Cited by 9
Cox, C. G., Salazar, C. R., Birnbaum, A. I., Witbracht, M. G., Tam, S. P., Thai, G. T., Sajjadi, S. A., Gillen, D. L., & Grill, J. D. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.10 · Cited by 8
Exploring the neuroprotective role of physical activity in cerebral small vessel disease
Anderson, M. E., Wind, E. J., & Robison, L. S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148884 · Cited by 9
Sideman, A., de Jesús, A. H., Alagappan, C., Ma, M., Koenig, C. J., Alving, L., Segal-gidan, F., Goldberger, R., Sohmer, D., & Rosen, H. J. (2024) · Medical Care Research and Review · doi:10.1177/10775587241251868 · Cited by 7
Alzheimer’s Disease, Biomarkers, and mAbs — What Does Primary Care Need?
Chin, N. A., & Erickson, C. M. (2024) · New England Journal of Medicine · doi:10.1056/nejmp2401854 · Cited by 8
Reshma, A., Subramanian, A., Kumarasamy, V., Tamilanban, T., Sekar, M., Gan, S. H., Subramaniyan, V., Wong, L. S., Rani, N. N. I. M., & Wu, Y. S. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13587 · Cited by 8
Epilepsy is associated with the accelerated aging of brain activity in sleep
Hadar, P., Westmeijer, M., Sun, H., Meulenbrugge, E., Jin, J., Paixao, L., Tesh, R. A., Cardoso, M. D. S., Arnal, P. J., Au, R., et al. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1458592 · Cited by 8
Merritt, V. C., Zhang, R., Sherva, R., Ly, M. T., Marra, D. E., Panizzon, M. S., Tsuang, D. W., Hauger, R. L., The MVP Cognitive Decline and Dementia During Aging Working Group, V. M. V. P., & Logue, M. W. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241299130 · Cited by 10
Eligibility for donanemab trial in a population-based study of cognitive aging
Jones, K. E., Aakre, J. A., Castillo, A. M., Ramanan, V. K., Kremers, W. K., Jack, C. R., Vemuri, P., Schwarz, C. G., Lowe, V. J., Knopman, D. S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100088 · Cited by 8
Self-citationCerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update
Weidauer, S., & Hattingen, E. (2025) · Biomedicines · doi:10.3390/biomedicines13030603 · Cited by 11
pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
Hulse, J. P., Maphis, N. M., Peabody, J., Bondu, V., Chackerian, B., & Bhaskar, K. (2025) · npj Vaccines · doi:10.1038/s41541-025-01147-4 · Cited by 9
Choi, S. H., Kim, S., Ong, P. A., Chin, A., Dominguez, J. C., Chen, C., Senanarong, V., Hu, C. J., Tripathi, M., Mok, V., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100215 · Cited by 9
It is time to share Alzheimer biomarker results in dementia with Lewy bodies
Armstrong, M. J., Grill, J. D., & Tropea, T. F. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70144 · Cited by 8
da Silva, A. M. P., Falcão, L., Ribeiro, F. V., Menezes, I. R., Leite, M. G. H. S. J., Farias, E., Nascimento, M., Han, M. L., Telles, J. P. M., Franco, E. D. S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361044 · Cited by 8
Collij, L. E., Mattsson, N., Janelidze, S., Ossenkoppele, R., & Hansson, O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70763 · Cited by 8
Li, S., Gao, Y., Zhang, X., Lang, J., Liu, X., Zhang, Y., Zhang, J., Zhao, Y., Cui, C., Gao, X., et al. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01738-z · Cited by 8
Cerman, J., Škorvagová, A., Vyhnálek, M., Veverová, K., Dvořák, K., Kozák, Š., Kavka, A., & Hort, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-23759-5 · Cited by 9
Langbaum, J. B. S., Bradbury, A. R., Egleston, B. L., Wood, E. M., Langlois, C. M., Largent, E. A., Harkins, K. A., Erickson, C. M., Stites, S. D., Oyen, E., et al. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100778 · Cited by 8
Lecanemab appropriate use recommendations for clinical practice in the UK
Mummery, C. J., Rasmussen, J., Blackburn, D. J., Coulthard, E. J., Davies, R., Dorsey, R., Fox, N. C., Hosseini, A. A., Ivenso, C., Jones, M. S., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336597 · Cited by 11
Zhang, W., Duan, L., Wang, C., Liao, Y., Zhao, R., Li, Z., Zhang, H., Wang, Z., & Zhang, J. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.12.007 · Cited by 8
Roh, H. W., Chang, Y. Y., Kim, K. Y., Jeon, S. Y., Wang, S., Kim, E., Bae, J. N., & Ryu, S. (2026) · Psychiatry Investigation · doi:10.30773/pi.2025.0400 · Cited by 8
Sato, K., Niimi, Y., Ihara, R., Suzuki, K., Iwata, A., & Iwatsubo, T. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2023.1320329 · Cited by 8
Weber, D. M., Kim, J. C., Goldman, S. M., Clarke, N. J., & Racke, M. K. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241246537 · Cited by 8
Momota, Y., Bun, S., Hirano, J., Kamiya, K., Ueda, R., Iwabuchi, Y., Takahata, K., Yamamoto, Y., Tezuka, T., Kubota, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58223-3 · Cited by 8
Promoting Growth in Behavioral Neurology: A Path Forward
Bateman, J. R., Josephy‐Hernandez, S. E., Apostolova, L. G., Benjamin, S., Barrett, A. M., Boeve, B. F., Budson, A. E., Chemali, Z. N., Lin, C.-Y. R., Daffner, K. R., et al. (2024) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000368 · Cited by 8
Self-citationBian, Z.-Y., Li, P., Feng, X.-Y., Zhou, Y., Cheng, F.-Y., Dong, W.-X., Xiang, P., & Tang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116794 · Cited by 8
Chu, C., Wang, Y., Ma, L., Mutimer, C. A., Ji, G., Shi, H., Yassi, N., Masters, C. L., Goudey, B., Jin, L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14583 · Cited by 8
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
